Positive News SentimentPositive NewsNASDAQ:NKTX Nkarta (NKTX) Stock Forecast, Price & News $1.50 -0.19 (-11.24%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$1.48▼$1.6450-Day Range$1.59▼$2.2952-Week Range$1.48▼$14.57Volume910,190 shsAverage Volume457,425 shsMarket Capitalization$73.59 millionP/E RatioN/ADividend YieldN/APrice Target$18.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Nkarta MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside1,144.4% Upside$18.67 Price TargetShort InterestBearish6.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2,436 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.77) to ($2.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector461st out of 969 stocksPharmaceutical Preparations Industry207th out of 455 stocks 3.4 Analyst's Opinion Consensus RatingNkarta has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.67, Nkarta has a forecasted upside of 1,144.4% from its current price of $1.50.Amount of Analyst CoverageNkarta has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.52% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Nkarta has recently increased by 4.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NKTX. Previous Next 3.3 News and Social Media Coverage News SentimentNkarta has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nkarta this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows7 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,436.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Nkarta are expected to grow in the coming year, from ($2.77) to ($2.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nkarta (NASDAQ:NKTX) StockNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More NKTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTX Stock News HeadlinesSeptember 28, 2023 | markets.businessinsider.comPromising Prospects for Ventyx Biosciences: A Comprehensive Analysis of VTX002’s Potential in Ulcerative Colitis TreatmentSeptember 9, 2023 | benzinga.comNkarta Stock (NASDAQ:NKTX), Analyst Ratings, Price Targets, PredictionsSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 14, 2023 | nasdaq.comMizuho Maintains Nkarta (NKTX) Buy RecommendationAugust 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Ventyx Biosciences (VTYX)August 11, 2023 | msn.comHC Wainwright & Co. Reiterates Nkarta (NKTX) Buy RecommendationAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Nkarta (NKTX)August 11, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for NkartaSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 10, 2023 | finanznachrichten.deNkarta, Inc.: Nkarta Reports Second Quarter 2023 Financial Results and Corporate HighlightsAugust 10, 2023 | finance.yahoo.comNkarta Reports Second Quarter 2023 Financial Results and Corporate HighlightsJuly 6, 2023 | msn.comNkarta (NKTX) Price Target Decreased by 25.24% to 20.02July 5, 2023 | finance.yahoo.comNkarta Appoints Alyssa Levin Chief Financial and Business OfficerJune 29, 2023 | msn.comRaymond James Maintains Nkarta (NKTX) Outperform RecommendationJune 28, 2023 | finance.yahoo.comHere's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 WeeksJune 28, 2023 | msn.comHC Wainwright & Co. Maintains Nkarta (NKTX) Buy RecommendationJune 28, 2023 | msn.comNeedham Maintains Nkarta (NKTX) Buy RecommendationJune 27, 2023 | benzinga.comNeedham Maintains Buy on Nkarta, Lowers Price Target to $19June 27, 2023 | bizjournals.comWhy Wall Street shaved a third of Peninsula cancer cell therapy company's value despite good newsJune 27, 2023 | markets.businessinsider.comNKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development TimelineJune 27, 2023 | markets.businessinsider.comNeedham Keeps Their Buy Rating on Nkarta (NKTX)June 27, 2023 | msn.comNkarta's Updated Data From Leukemia Study Fails To Cheer InvestorsJune 27, 2023 | msn.comNkarta off 34% after updating early-stage data for leukemia therapyJune 27, 2023 | markets.businessinsider.comAnalyst Expectations for Nkarta's FutureJune 27, 2023 | finance.yahoo.comWhy Shares of Nkarta Are Slumping TuesdayJune 27, 2023 | finance.yahoo.comNkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid LeukemiaJune 26, 2023 | finance.yahoo.comNkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy ProgramSee More Headlines Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTX Company Calendar Last Earnings8/10/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees169Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.67 High Stock Price Forecast$26.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+1,144.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.83% Return on Assets-26.83% Debt Debt-to-Equity RatioN/A Current Ratio10.77 Quick Ratio10.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.63 per share Price / Book0.20Miscellaneous Outstanding Shares49,060,000Free Float46,311,000Market Cap$73.59 million OptionableNot Optionable Beta-0.06 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Paul J. Hastings (Age 63)CEO, Pres & Director Comp: $938.41kDr. Alicia J. Hager (Age 53)Chief Legal Officer & Corp. Sec. Comp: $590.94kMs. Alyssa Levin C.A. (Age 38)CPA, Chief Financial & Bus. Officer and Principal Accounting Officer Dr. Ralph Brandenberger Ph.D. (Age 54)Chief Technical Officer Dr. James Trager Ph.D. (Age 59)Ph.D., Chief Scientific Officer Ms. Yvonne Li M.B.A. (Age 63)Chief Admin. Officer Mr. Greg MannVP of Public Affairs and Investor RelationsDr. David R. Shook M.D. (Age 45)Chief Medical Officer More ExecutivesKey CompetitorsSyros PharmaceuticalsNASDAQ:SYRSBioXcel TherapeuticsNASDAQ:BTAIVaccinexNASDAQ:VCNXLumiraDxNASDAQ:LMDXCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsBarclays PLCSold 17,697 shares on 9/21/2023Ownership: 0.769%David ShookSold 1,331 sharesTotal: $2,435.73 ($1.83/share)Public Employees Retirement System of OhioBought 32,730 shares on 8/15/2023Ownership: 0.281%Goldman Sachs Group Inc.Bought 33,358 shares on 8/15/2023Ownership: 0.195%Wells Fargo & Company MNBought 5,063 shares on 8/15/2023Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions NKTX Stock - Frequently Asked Questions Should I buy or sell Nkarta stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NKTX shares. View NKTX analyst ratings or view top-rated stocks. What is Nkarta's stock price forecast for 2023? 5 brokers have issued 1 year target prices for Nkarta's shares. Their NKTX share price forecasts range from $15.00 to $26.00. On average, they expect the company's share price to reach $18.67 in the next year. This suggests a possible upside of 1,144.4% from the stock's current price. View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts. How have NKTX shares performed in 2023? Nkarta's stock was trading at $5.99 at the beginning of the year. Since then, NKTX stock has decreased by 75.0% and is now trading at $1.50. View the best growth stocks for 2023 here. When is Nkarta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our NKTX earnings forecast. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.01. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG). When did Nkarta IPO? (NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. What is Nkarta's stock symbol? Nkarta trades on the NASDAQ under the ticker symbol "NKTX." Who are Nkarta's major shareholders? Nkarta's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (9.63%), BlackRock Inc. (6.20%), Geode Capital Management LLC (1.35%), State Street Corp (1.22%), JPMorgan Chase & Co. (0.78%) and Barclays PLC (0.77%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nkarta's stock price today? One share of NKTX stock can currently be purchased for approximately $1.50. How much money does Nkarta make? Nkarta (NASDAQ:NKTX) has a market capitalization of $73.59 million. The company earns $-113,840,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. How many employees does Nkarta have? The company employs 169 workers across the globe. How can I contact Nkarta? Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.nkartatx.com. The company can be reached via phone at 925-407-1049 or via email at gmann@nkartatx.com. This page (NASDAQ:NKTX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.